Kinase inhibitor

po文清單
文章推薦指數: 80 %
投票人數:10人

關於「Kinase inhibitor」標籤,搜尋引擎有相關的訊息討論:

A comprehensive review of protein kinase inhibitors for cancer therapy2018年10月9日 · The advent of protein kinase inhibitors in cancer therapy has led to a paradigm ... by FDA for the treatment of relapsed follicular lymphoma (FL).Tyrosine kinase inhibitors: Multi-targeted or single-targeted?2011年2月10日 · Different tyrosine kinase inhibitors have various mechanisms to achieve ... Keywords: Tyrosine kinase inhibitors, Targeted therapy, Epidermal ... Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, et al. ... Facebook; Share on Twitter ...Unprecedently Large-Scale Kinase Inhibitor Set Enabling the ...2016年8月2日 · Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate ... J. S.; Trainor, G. L.; Loughney, D. A.; Johnson, S. R. Trends in kinase ...Advances in studies of tyrosine kinase inhibitors and their acquired ...2018年2月19日 · Protein tyrosine kinase (PTK) is one of the major signaling enzymes in ... Tyrosine kinase inhibitors (TKIs) compete with ATP for the ATP ... Blair HA, Plosker GL. ... BMC Twitter page · BMC Facebook page · BMC Weibo page.Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in ...2015年9月14日 · Activity of approved ABL1 tyrosine kinase inhibitors (TKIs; bosutinib, ... C Louvet, GL Szot, J Lang , etal: Tyrosine kinase inhibitors reverse type ...Clonal expansion of T/NK-cells during tyrosine kinase inhibitor ...2009年3月19日 · Dasatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), ... Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al.Evaluation of Tyrosine Kinase Inhibitor Combinations for ... - PLoS2012年10月2日 · ... Loilome W, Siu I-M, Tyler B, Gallia GL, Riggins GJ (2012) Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy.Special Report: Next-gen kinase inhibitors march toward market ...2020年9月17日 · Finding novel kinase inhibitors and drugs that can combat resistance to them is a priority in oncology research. (ESB Professional/Shutterstock).Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor ...2019年12月12日 · Abstract Background Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive ...TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor ...2019年4月1日 · Lapatinib, a reversible HER2 and EGFR dual kinase inhibitor, is used in ... 400 μmol/L ATP, 10 mmol/L MnCl2, and 0.5 μmol/L FL-peptide 22. ... Drilon A,; Laetsch TW,; Kummar S,; DuBois SG,; Lassen UN,; Demetri GD,; et al.


請為這篇文章評分?